FDA Roadblock Freezes Longevity Breakthrough

Smiling woman receiving a vaccination from a healthcare worker — Photo: Pixel-Shot / Shutterstock

The pills that might slow down aging itself may already be sitting in your medicine cabinet, prescribed for something else entirely.

Story Snapshot

Doctor Nir Barzilai leads a research push to repurpose already-approved drugs to fight aging, not just single diseases.
His team names four top candidates: metformin, SGLT2 inhibitors, bisphosphonates, and GLP-1 drugs like Ozempic.
The Food and Drug Administration (FDA) does not approve any drug for aging itself, only for specific diseases.
His TAME trial concept aims to test whether one drug can delay several age-related diseases at once.

A Doctor’s Search For Drugs That Already Exist

Doctor Nir Barzilai directs the Institute for Aging Research at Albert Einstein College of Medicine. He has spent decades studying centenarians, hunting for clues about why some people live past 100 in good health. That work led him to a bold idea. Instead of inventing brand-new anti-aging drugs from scratch, why not test medicines doctors already prescribe every day?

Barzilai and his coauthors laid out this plan in a 2022 paper in the journal Aging Cell. They proposed a standardized way to screen FDA-approved drugs for their potential to slow aging biology. The idea is not to wait ten or twenty years for a brand-new pill. It is to look at drugs already sitting on pharmacy shelves and ask if they do more than treat diabetes or bone loss.

In a 2024 update published in Medical Research Archives, Barzilai and coauthor Maryanne Leone narrowed the list to four leading candidates. They named metformin, SGLT2 inhibitors, bisphosphonates, and GLP-1 receptor agonists as the top drugs worth studying for their effect on aging. Metformin treats type 2 diabetes. SGLT2 inhibitors also treat diabetes. Bisphosphonates treat bone loss. GLP-1 drugs, now famous for weight loss, treat diabetes and obesity.

Why One Pill Might Fight Many Diseases At Once

Barzilai’s core argument is simple. Aging itself is the biggest risk factor for cancer, heart disease, diabetes, and memory loss. He has said that targeting the biology of aging means you do not just prevent one disease. You prevent all of them at the same time. That is a very different goal than treating each illness one by one after it shows up.

This thinking sits behind his long-running TAME study, short for Targeting Aging with MEtformin. Barzilai described TAME as a placebo-controlled trial built to test whether metformin can delay a group of age-related conditions together, including cancer, heart disease, diabetes, and mental decline. His stated goal is to convince the FDA to recognize aging itself as a condition doctors can treat.

At a 2025 conference talk, Barzilai stressed a practical point often lost in the science. These four drug classes already carry established safety records because millions of patients have taken them for years. That means physicians can legally prescribe them off-label right now, without waiting for a new approval process.

The Regulatory Wall Standing In The Way

Here is the catch nobody disputes, including Barzilai’s own team. No drug currently holds FDA approval specifically for aging, because the agency does not classify aging as a disease with its own diagnostic criteria. Every approval requires a specific illness and a specific measurable outcome. Aging does not fit neatly into that box, no matter how promising the underlying biology looks.

That regulatory gap explains why Barzilai’s four-drug shortlist relies on evidence gathered from other studies, not one clean trial built around an aging outcome. Broader research in the field echoes this limitation. A 2025 review noted that no longevity drug has yet proven its effectiveness in a high-quality randomized trial measuring aging directly, rather than a single disease. That is not a knock on the science. It is a description of where the finish line still sits.

For readers watching their own health choices, the practical takeaway is grounded rather than magical. These are not exotic supplements sold on late-night television. They are mainstream, well-studied prescription drugs already trusted by millions of patients for other conditions. Barzilai’s mission is not to sell a miracle. It is to prove, through rigorous trials, that medicine already has more anti-aging power than regulators currently recognize.